References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
- Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009; 27:147-63; PMID:19302037; http://dx.doi.org/10.1146/annurev.immunol.021908.132629
- Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6:595-601; PMID:16868550; http://dx.doi.org/10.1038/nri1901
- Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002; 17:537-47; PMID:12433361; http://dx.doi.org/10.1016/S1074-7613(02)00429-6
- Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, Sprent J. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A 2006; 103:9166-71; PMID:16757567; http://dx.doi.org/10.1073/pnas.0600240103
- Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, Plet A, Jacques Y. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R betagamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 2006; 281:1612-9; PMID:16284400; http://dx.doi.org/10.1074/jbc.M508624200
- Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ. Interleukin-15interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. CancerRres 2008; 68:2972-83; PMID:18413767; http://dx.doi.org/10.1158/0008-5472.CAN-08-0045
- Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, Tan X, Sutton SE, Cooke MP, Ohlén C et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006; 12:335-41; PMID:16474399; http://dx.doi.org/10.1038/nm1359
- Cheng L, Du X, Wang Z, Ju J, Jia M, Huang Q, Xing Q, Xu M, Tan Y, Liu M et al. Hyper-IL-15 suppresses metastatic and autochthonous liver cancers by promoting tumor-specific CD8+ T cell responses. J Hepatol 2014; pii: S0168–8278(14)00472-3; PMID:25016226; http://dx.doi.org/10.4161/21624011.2014.963409